Study of Sulphoraphane in Chronic Kidney Disease

Inclusion Criteria:

eGFR ≥ 20 and <60 ml/min/m2/year, and a decline in eGFR of ≥ 3 ml/min/m2/year in the previous 12 months
Blood pressure <140/90 mm Hg prior to initiation of sulphoraphane
stable anti-hypertensive regimen for at least one month prior to initiation of sulphoraphane or successful run-in period
able to provide consent
able to swallow capsules

Exclusion Criteria:

significant co-morbid conditions with life expectancy of <1 year
uncontrolled hypertension
serum potassium of >5.5 mEq/L at screening
New York Heart Association Class 3 or 4 heart failure symptoms, known EF ≤30% or hospital admission for heart failure within the past 3 months
factors judged to limit adherence to interventions
current participation in another study
pregnancy or planning to become pregnant or currently breastfeeding
history of dementia
on anticoagulants or immunosuppression
under treatment for cancer